Hydrogen Capsules Help Liver Disease Patient Recover Faster
- Authors
- Yun-Ting Lin, Jeng-Wei Lu, Jung-Chun Lin, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Hsiao-Chen Liu, Kuang-Yih Wang, Feng-Cheng Liu
- Journal
- In Vivo
- Year
- 2025
- DOI
- 10.21873/invivo.13968
- Study Type
- Human
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- Taiwan
- Health Condition
- Primary Biliary Cholangitis
- Body System
- Hepatic
TL;DR
Molecular hydrogen capsules improved liver health and immune function in a patient with a chronic autoimmune liver disease not fully helped by standard treatment.
Key Finding
In one patient with PBC inadequately controlled by standard therapy, adding molecular hydrogen capsules for four months reduced liver enzymes (AST from 279 to 95 U/l, ALT from 183 to 70 U/l) and normalized immune markers previously abnormal during disease flares.
Summary
This case report describes one 44-year-old man with primary biliary cholangitis (PBC), a chronic disease where the immune system damages bile ducts in the liver, who was not responding well to standard treatment. When molecular hydrogen capsules were added to his existing medication over four months, his liver enzyme levels improved significantly, immune markers normalized, and he reported feeling less tired and itchy. However, this is a single patient's experience, not a controlled study.
Practical Takeaway
While this case suggests molecular hydrogen capsules may have potential as an add-on treatment for PBC, this is only one patient's experience and cannot establish whether the improvement was due to the hydrogen, time, or other factors. Much larger controlled studies are needed before any conclusions can be drawn about effectiveness. Anyone with PBC considering this should discuss it with their doctor.
Abstract
Background/aim: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by bile duct destruction, cholestasis, and inflammation, often leading to fibrosis and cirrhosis. While ursodeoxycholic acid (UDCA) is the standard treatment, some patients exhibit suboptimal responses, necessitating adjunctive therapies. Molecular hydrogen (H2), known for its antioxidant and anti-inflammatory properties, has shown potential in mitigating oxidative stress and immune dysregulation in autoimmune liver diseases. This case report evaluates the therapeutic efficacy of H2 capsules in managing PBC with elevated liver enzymes and immune dysregulation. Case report: A 44-year-old male with PBC, splenomegaly, and elevated IgG4 levels presented with acute cholestatic hepatitis. Laboratory tests revealed significantly elevated aspartate transaminase (AST) (279 U/l) and alanine aminotransferase (ALT) (183 U/l). Despite UDCA therapy, liver enzymes remained persistently high. On August 30, 2024, molecular hydrogen capsule therapy was introduced as adjunctive treatment. Over four months, AST and ALT levels declined to 95 U/l and 70 U/l, respectively, without adverse effects. Immune markers (KLRG-1, PD-1, and Tim3), previously reduced during PBC flares, normalized post-treatment. Imaging confirmed stable fibrosis, and IgG4 levels decreased, suggesting reduced autoimmune activity. The patient also reported improvements in fatigue and pruritus, enhancing overall quality of life. Conclusion: Molecular hydrogen capsules therapy may serve as a safe and effective adjunctive treatment for PBC, contributing to improved liver enzyme levels, immune regulation, and patient well-being. Further studies are warranted to validate these findings and establish standardized treatment protocols in autoimmune liver diseases.